pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
pharmaceutical investing Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film
pharmaceutical investing Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
pharmaceutical investing Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm Sublingual Film
pharmaceutical investing Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
pharmaceutical investing Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635
pharmaceutical investing Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
pharmaceutical investing Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Copper Quest Announces Fully Subscribed Private Placement with Continued Support by Strategic International Investor
LaFleur Minerals Appoints Andrew Elinesky as Chief Executive Officer and Provides Update on Beacon Gold Mill Recommissioning Work and Swanson Bulk Sample Progress
